Pharmaceutical Supply of Oxymetazoline Hydrochloride

The contract involves the supply of FDA-approved oxymetazoline hydrochloride in bulk form for integration into military medical kits destined for use aboard a U.S. Navy vessel. The substance is a vasoconstrictor commonly used in emergency medical scenarios to manage bleeding and nasal congestion, ensuring readiness for field medical operations. The procurement is managed under a subcontract by the Defense Logistics Agency, part of the Department of Defense, and falls under the NAICS code 325412, which classifies pharmaceutical and biological product manufacturing. Delivery must meet strict pharmaceutical standards to ensure purity, potency, and compliance with military medical protocols, and the product must be packaged and labeled for secure storage and immediate access in combat or expeditionary environments. The contract was posted on May 31, 2026, with no specific set-aside designation for small or disadvantaged businesses, indicating open competition among qualified suppliers. The place of performance is not explicitly defined beyond the delivery to a Navy vessel, implying logistics coordination will be managed through DLA’s existing distribution infrastructure. The reference number SPE2DX25D9822 and related delivery identifier SPE2D226F2733 are key for tracking order fulfillment and compliance. All shipments must align with federal pharmaceutical regulations and military specifications, with quality assurance verification required prior to acceptance aboard the vessel. The contract underscores the Department of Defense’s commitment to maintaining a reliable, pre-positioned pharmaceutical supply chain for critical medical needs in naval operations.